- A small study showed promising results in using semaglutide to treat people with type 1 diabetes.
- Type 1 diabetes is traditionally treated with daily insulin injections while semaglutide is only approved for people with type 2 diabetes.
- Researchers want to expand their work to see if their results can be replicated.
- If findings continue to show promise, this could represent a significant change in the understanding and treatment of type 1 diabetes.
Researchers from the University at Buffalo are hoping that their recent findings could pave the way to a new way of treating type 1 diabetes – one that could reduce, or even eliminate altogether, the need for insulin shots.
The findings from the small study were published this week in the New England Journal of Medicine.
Researchers took study participants with a new diagnosis of type 1 diabetes and treated them not with the traditional insulin shots, but with a semaglutide – a GLP-1 agonist used to treat type 2 diabetes that is sold under brand names such as Rybelsus and Ozempic.
The researchers said the findings were promising but will require further research and more studies to see if the results can be replicated.
However, if the results hold true, researchers say it could lead to a shift in the way that type 1 diabetes is treated.
In people with diabetes, there are issues with how the body turns food into energy.
Insulin, which is released by the pancreas to regulate how the body’s cells turn blood sugar into energy, is either ineffective or produced in insufficient quantities in a person with diabetes.
There are
Type 1 diabetes…
Read the full article here